By silencing an anti-apoptotic protein (Bcl-2) in an assay with ameloblastoma cells, the authors of this study observed an inhibition of tumour formation in vivo and suggested that studying apoptosis modulators may favour the prediction of recurrences and the development of effective chemotherapeutic agents for treating these lesions27. This evidence concerns the gene BCL2 and ameloblastoma.